Physician profile
Gurvinder S Deol
NPI 1467487025
$2,657,914.19
in general payments reported to CMS, 2019-2025
29 companies · $505K in 2025
The $505K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317K · 2020: $268K · 2021: $307K · 2022: $366K · 2023: $312K · 2024: $583K · 2025: $505K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.0M · Consulting Fee: $274K · Travel and Lodging: $51K · Food and Beverage: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,913 · Education: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,041,719.49 |
| Consulting Fee | $273,812.50 |
| Travel and Lodging | $51,327.73 |
| Food and Beverage | $23,751.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,912.50 |
| Education | $309.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $1,061,155.19 | 2019-2025 | Other - Miscellaneous, Safeop, Battalion Tlif - Pc |
| Nuvasive, INC. | $715,920.88 | 2019-2023 | Coroent, Coalesce, Reline |
| Cerapedics INC. | $308,857.68 | 2019-2024 | I-Factor Peptide Enhanced Bone Graft |
| Globus Medical, INC. | $261,620.27 | 2019-2025 | Reline, Cohere, Excelsiusgps |
| Orthofix Medical, INC. | $151,591.07 | 2023-2025 | Admiral, Physio-Stim, Shoreline Asc |
| Seaspine Orthopedics Corporation | $64,126.15 | 2019-2022 | |
| Axis Spine Technologies INC. | $52,887.43 | 2021-2025 | Axis Spine Technologies Alif Implant, Alif, Axis Spine Technologies Alif |
| Si-Bone, INC. | $11,240.37 | 2019-2024 | |
| Sanara Medtech INC. | $10,681.05 | 2022-2025 | Celleraterx, Celleraterx |
| Medtronic USA, INC. | $5,261.57 | 2019-2020 | |
| Medtronic, INC. | $4,445.09 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Unid_pass |
| Boston Scientific Corporation | $3,187.16 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Restor3d, INC. | $2,748.98 | 2022-2025 | |
| Synthes Gmbh | $1,125.00 | 2021 | |
| Spinal Simplicity, LLC | $513.16 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $406.37 | 2022-2024 | Iovera, Zilretta, Exparel |
| Arteriocyte Medical Systems, INC. | $405.92 | 2022 | |
| Providence Medical Technology, INC. | $370.71 | 2023-2024 | |
| Mml US, INC. | $343.47 | 2021-2023 | Reactiv8 |
| Next Science LLC | $293.28 | 2020 | |
| Intrinsic Therapeutics | $174.00 | 2025 | Barricaid Acd (Annular Closure Device) |
| Abbott Laboratories | $168.02 | 2025 | Eterna |
| Carlsmed, INC. | $122.33 | 2024 | Aprevo |
| Biocomposites INC | $121.21 | 2024 | |
| Bioventus LLC | $45.24 | 2019 | |
| Becton, Dickinson and Company | $43.22 | 2025 | Hemosphere |
| Zimvie INC. | $38.20 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $21.17 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$441,804.36 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurvinder Deol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.